Morepen LaboratoriesQ4 FY22

Morepen Laboratories Q4 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹94.66P/E: 27.5Market Cap: ₹5.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • Health and pharmaceutical business is growing exponentially with no anticipated market decline.
  • Long-term focus includes API development, power integration, new segments, and increased exports.
  • Expectations for business stabilization may take 1-2 more quarters to return to desired growth.
  • Medical devices, especially Glucometers and BP monitors, expected to drive growth over next 3-4 quarters.
  • Finished dosage business growing steadily with 28% yearly increase; strong growth in antibiotics, probiotics, nutrition, and OTC segments.
  • Online OTC business rapidly expanding, growing 273% in small base.
  • Export market focus with regulatory approvals sought to expand international presence.
  • Product portfolio expansion ongoing, including post-patent products like Sitagliptin.
  • Market competition expected, but growth opportunities remain strong due to "Make in India" and PLI schemes.
  • Operating margins targeted to improve from Q1 onwards, aiming to maintain previous 7-10% range.

See what Morepen Laboratories management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • Morepen Laboratories has not closed any new investment proposal yet; they remain open to financing options but have not finalized any fundraising.
  • The company is a zero-debt entity currently and has no borrowings.
  • They face constraints growing working capital since they rely mainly on internal accruals and have not taken bank working capital loans, partly due to their CDR tag and preference capital issue limiting bank support for borrowings.
  • Future growth strategies include finding solutions for working capital needs, possibly through better financing arrangements.
  • Promoters have recently subscribed to warrants worth Rs. 2.8 crores as part of capital raise.
  • No concrete plans announced for major debt or equity fundraises as of the date (May 6, 2022), but they remain open to investment opportunities for growth.

See what Morepen Laboratories management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Morepen Laboratories does not have any major capex currently planned; ongoing capex is divided between working capital and capital expenditure (Page 22).
  • The company's growth is primarily funded through internal accruals and capital from warrant subscription, without bank borrowings (Page 22).
  • Working capital requirements are increasing due to growth, and this constrains the ability to invest heavily in capex (Page 18).
  • The company is open to exploring investment opportunities but hasn't closed any specific proposals yet (Page 14).
  • For medical devices, expansion involves adding new products like nebulizers, weighing scales, and air purifiers, with licenses and production capacity being worked on—some products may be launched by September quarter (Page 19).
  • International market expansion in medical devices is planned, pending certifications and audits (Page 19).

Track Morepen Laboratories — get its next earnings analysis in your feed

How does Morepen Laboratories rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisMorepen Laboratories
Rev 2Mar 3

How does Morepen Laboratories rank in Pharmaceuticals & Biotechnology?

Compare Morepen Laboratories against every Pharmaceuticals & Biotechnology company (Q4 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →